MedPath

Hyaluronidase (human recombinant)

Generic Name
Hyaluronidase (human recombinant)
Brand Names
Darzalex Faspro, Herceptin Hylecta, Hylenex, Hyqvia 5 G / 50 Ml Kit, Phesgo, Rituxan Hycela, Vyvgart Hytrulo
Drug Type
Biotech
Chemical Formula
-
CAS Number
757971-58-7
Unique Ingredient Identifier
743QUY4VD8
Background

A purified preparation of the enzyme recombinant human hyaluronidase. Hyaluronidase (human recombinant) (INN Vorhyaluronidase alfa) is produced by genetically engineered Chinese Hamster Ovary (CHO) cells containing a DNA plasmid encoding for a soluble fragment of human hyaluronidase (PH20). Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents. The action of hyaluronidase was first described in 1936, and named in 1939. Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permeability of the connective tissue. Hyaluronidase has been used in surgical settings for at least the past 60 years to improve the diffusion of local anesthetics.

Hyaluronidase was first used in prescription products in the United States on 5 May 2004.

Indication

Hyaluronidase is indicated for subcutaneous fluid administration for hydration, and increasing resorption of radiopaque agents in subcutaneous urography. Hyaluronidase is also indicated by multiple routes to increase the dispersion of other injectable drugs.

Associated Conditions
Drug Extravasation, Generalized Myasthenia Gravis, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Primary Immune Deficiency Disorders (PIDD), Primary Immunodeficiency, Secondary humoral immunodeficiency, Stage I Breast Cancer
Associated Therapies
Parenteral rehydration therapy, Improving resorption of radiopaque agents, To increase percutaneous drug absorption therapy
Clinical Trials
Related News
marketscreener.com
·

Johnson & Johnson Submits Applications in the U.S. and EU Seek Approval of DARZALEX

Johnson & Johnson submits regulatory applications to FDA and EMA for DARZALEX FASPRO and DARZALEX SC, targeting high-risk smoldering multiple myeloma. AQUILA study (NCT03301220) investigates DARZALEX FASPRO versus active monitoring in 390 patients, focusing on progression-free survival. Smoldering multiple myeloma, an asymptomatic precursor to multiple myeloma, affects 15% of newly diagnosed cases, with half of high-risk patients progressing within two years. Multiple myeloma, a blood cancer affecting plasma cells, is the second most common blood cancer globally, with an estimated 35,000 new cases and 12,000 deaths in the U.S. in 2024.

Related Clinical Trials:

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
prnewswire.com
·

Johnson & Johnson submits applications in the U.S. and EU seeking approval of ...

Johnson & Johnson submits regulatory applications to FDA and EMA for DARZALEX FASPRO® as a treatment for high-risk smoldering multiple myeloma, supported by Phase 3 AQUILA study data.

Related Clinical Trials:

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
simplywall.st
·

Three Value Stocks Priced Below Estimated Worth In November 2024

Investors focus on undervalued stocks with strong fundamentals amid market volatility. Top 10 undervalued stocks include Provident Financial Services, Proya Cosmetics, Arteche Lantegi Elkartea, Elica, Beyout Investment Group, Bangkok Genomics Innovation, BayCurrent Consulting, Redcentric, Beijing LeiKe Defense Technology, and Alnylam Pharmaceuticals. argenx SE, GFL Environmental Inc., and Dino Polska S.A. are highlighted for their significant discounts to fair value based on cash flow analysis.
finance.yahoo.com
·

Pharma Stock Roundup: RHHBY Earnings, Drug Pipeline & Regulatory News

Roche reported strong Q3 and nine-month results, with sales up 9% at constant exchange rates. Sanofi is in exclusive talks with CD&R to sell a controlling stake in its consumer healthcare business, Opella. The FDA approved Pfizer’s RSV vaccine, Abrysvo, for adults under 60. Novo Nordisk’s cardiovascular outcomes study on oral semaglutide met its primary endpoint, and AstraZeneca’s Wainzua received a positive CHMP recommendation for EU approval.
pharmaceutical-technology.com
·

Roche wins first-line approval for PI3K inhibitor combo in breast cancer

FDA approves Roche's Itovebi (inavolisib) in combo with Pfizer's Ibrance and AstraZeneca's Faslodex for HR+/HER2- breast cancer. Itovebi, a PI3K inhibitor, outperformed placebo in Phase III INAVO120 trial with 15 months PFS vs 7.3 months. Competitor Novartis's Piqray expected to see lower sales by 2030. Common Grade 3/4 adverse effects include haematological abnormalities and hyperglycaemia.

Related Clinical Trials:

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
myelomaresearchnews.com
·

J&J seeks new FDA approval of Darzalex Faspro myeloma combo

Johnson & Johnson seeks FDA approval for Darzalex Faspro-based quadruple regimen for newly diagnosed multiple myeloma patients not initially planning stem cell transplant. The D-VRd combo, already approved for transplant-eligible patients, showed significant benefits in the CEPHEUS trial, including higher MRD-negativity rates and reduced disease progression risk.

Related Clinical Trials:

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma
curetoday.com
·

FDA Receives Application to Review D-VRd in Multiple Myeloma Subset

Johnson & Johnson submitted an FDA application for Darzalex Faspro-based D-VRd regimen to treat newly diagnosed multiple myeloma patients ineligible for transplant, based on CEPHEUS study results showing 60.9% MRD-negativity and 43% risk reduction for progression or death.
targetedonc.com
·

Major Advances in Multiple Myeloma: A Recap of the 2024 IMS Meeting

The 2024 International Myeloma Society Annual Meeting in Rio showcased advancements in multiple myeloma treatment, including promising results from trials like TRIMM-2, CEPHEUS, CARTITUDE-4, and RedirecTT-1, highlighting new therapies and improved outcomes for patients.

Related Clinical Trials:

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
prnewswire.com
·

Johnson & Johnson files for U.S. FDA approval of DARZALEX FASPRO®-based quadruplet

Johnson & Johnson submits sBLA to FDA for DARZALEX FASPRO® quadruplet regimen for newly diagnosed multiple myeloma patients, supported by CEPHEUS study showing 60.9% MRD-negativity and 43% reduced risk of progression or death.

Related Clinical Trials:

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy